Aprea Therapeutics Q2 FY26 net loss narrows to $3.59 million - APRE News | RalliesAprea Therapeutics Q2 FY26 net loss narrows to $3.59 million
A
APRE• Clinical progress in ACESOT-1051
- Enrollment accelerated in the Phase 1 ACESOT-1051 APR-1051 study, with active sites expanding to 10 from three.
- The next ACESOT-1051 clinical update is expected in Q4 2026; dose escalation and backfill expansion are targeted for completion in Q2 2027.
Second-quarter financial results
- Aprea Therapeutics posted a Q2 net loss of USD 3.59 million, or USD 0.07 per share, versus a USD 3.24 million loss.
- Operating loss widened to USD 4.03 million from USD 3.39 million; R&D expense rose to USD 2.46 million from USD 1.91 million.
- Cash and cash equivalents climbed to USD 41.23 million at June 30 from USD 14.6 million at Dec. 31, 2025.
VEON
•
